These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 19773538)

  • 1. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
    Xu L; Chen Y; Pan Y; Skiles GL; Shou M
    Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
    Chen Y; Liu L; Monshouwer M; Fretland AJ
    Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
    Polasek TM; Miners JO
    Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
    Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
    Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
    Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
    Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
    Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
    Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
    Albaugh DR; Fullenwider CL; Fisher MB; Hutzler JM
    Drug Metab Dispos; 2012 Jul; 40(7):1336-44. PubMed ID: 22490230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes.
    Aasa J; Hu Y; Eklund G; Lindgren A; Baranczewski P; Malmquist J; Turek D; Bueters T
    Drug Metab Dispos; 2013 Jan; 41(1):159-69. PubMed ID: 23073735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
    Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
    Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
    Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
    Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
    Zhang ZY; King BM; Pelletier RD; Wong YN
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
    Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
    Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
    Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
    Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
    Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
    Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
    Yadav J; Korzekwa K; Nagar S
    Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
    Lutz JD; VandenBrink BM; Babu KN; Nelson WL; Kunze KL; Isoherranen N
    Drug Metab Dispos; 2013 Dec; 41(12):2056-65. PubMed ID: 23785064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4.
    Rougée LRA; Bedwell DW; Hansen K; Abraham TL; Hall SD
    Drug Metab Dispos; 2023 Oct; 51(10):1372-1380. PubMed ID: 37524542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.